You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR SOLABEGRON

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Solabegron

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00343486 ↗	Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms	Completed	GlaxoSmithKline	Phase 2	This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.
NCT00394186 ↗	A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)	Completed	GlaxoSmithKline	Phase 2	This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.
NCT00401479 ↗	A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers	Completed	GlaxoSmithKline	Phase 1	This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.
NCT00427596 ↗	A Two-Part Study to Determine: Best Medication Formulation and Food Effect	Completed	GlaxoSmithKline	Phase 1	This is a two-part study. Part 1 is designed to find the best modified release formulation of GW423753; Part 2 is designed to use the selected formulation(s) from Part 1 to find out if food affects the way the medication is processed by the body.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Solabegron

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Overactive Bladder	5
Irritable Bowel Syndrome (IBS)	2
Healthy Subjects, Overactive Bladder	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Urinary Bladder, Overactive	6
Irritable Bowel Syndrome	2
Syndrome	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Solabegron

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	59
Germany	8
Australia	7
Argentina	3
France	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Michigan	2
Massachusetts	2
Louisiana	2
Georgia	2
Florida	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Solabegron

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	4
Phase 1	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Solabegron

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
GlaxoSmithKline	5
Velicept Therapeutics, Inc.	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.